PMID- 20101337
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20100623
LR  - 20211020
IS  - 1998-3611 (Electronic)
IS  - 0019-5154 (Print)
IS  - 0019-5154 (Linking)
VI  - 54
IP  - 4
DP  - 2009
TI  - Efficacy and tolerability of cefditoren pivoxil in uncomplicated skin and skin 
      structure infections in Indian patients.
PG  - 350-6
LID - 10.4103/0019-5154.57612 [doi]
AB  - BACKGROUND: Uncomplicated skin and skin structure infections (uSSSI) are commonly 
      encountered community-acquired infections and are typically confined to the 
      superficial layers of the skin. Hence, they seldom lead to the destruction of 
      skin structures. AIMS: To evaluate the efficacy and tolerability of cefditoren 
      pivoxil in uSSSI in Indian patients. METHODS: One hundred and seventy-eight 
      patients diagnosed with uncomplicated SSSI were enrolled in this randomized, 
      comparative, multicentric study. Patients received either cefditoren pivoxil or 
      cefdinir for ten days. Efficacy was assessed both clinically and 
      microbiologically. Safety evaluation consisted of reporting of type, frequency, 
      severity, and causal relationship of adverse events. RESULTS: One hundred and 
      fifty-one patients completed the study. Clinical and bacteriological efficacy of 
      cefditoren pivoxil was comparable to that of cefdinir in the treatment of uSSSI. 
      One hundred and five patients were eligible for per protocol (PP) analysis of 
      bacteriological outcome and clinical efficacy. Clinical cure or improvement was 
      achieved in 98.00% patients treated with cefditoren pivoxil and 98.18% patients 
      treated with cefdinir. In the modified Intent to Treat (mITT) patient population, 
      clinical cure or improvement was recorded in 97.33% patients treated with 
      cefditoren pivoxil and 96.20% patients treated with cefdinir. Microbiological 
      eradication (or presumed eradication) was recorded in 88.00% patients treated 
      with cefditoren pivoxil and 94.55% patients treated with cefdinir. The above 
      differences in the outcome rates between the two drugs were not statistically 
      significant. Six adverse events (AEs) (two in cefditoren group and four in 
      cefdinir group) were reported in this study. CONCLUSION: Cefditoren pivoxil 200 
      mg b.i.d. was effective and well tolerated in the treatment of uSSSI.
FAU - Manaktala, Charu
AU  - Manaktala C
AD  - Medical Affairs and Clinical Research, Ranbaxy Laboratories Ltd, 77-B, IFFCO 
      Road, Sector-18, Udyog Vihar Industrial Area, Gurgaon, Haryana, India. 
      charu.manaktala@ranbaxy.com
FAU - Singh, Amit Kumar
AU  - Singh AK
FAU - Verma, Manish
AU  - Verma M
FAU - Sachdeva, Asheesh
AU  - Sachdeva A
FAU - Sharma, Himanshu
AU  - Sharma H
FAU - Roy, Arjun
AU  - Roy A
FAU - Jalali, R K
AU  - Jalali RK
FAU - Gowrishankar, R
AU  - Gowrishankar R
FAU - Kumar, A
AU  - Kumar A
FAU - Kumar, A Sainath
AU  - Kumar AS
FAU - Jayaraman, A M
AU  - Jayaraman AM
FAU - Swarnkar, B
AU  - Swarnkar B
FAU - Srinivas, C R
AU  - Srinivas CR
FAU - Nayak, Chitra
AU  - Nayak C
FAU - Duttaroy, D
AU  - Duttaroy D
FAU - Umrigar, D
AU  - Umrigar D
FAU - Jesudanam, Madhuri
AU  - Jesudanam M
FAU - Maheshwari, N
AU  - Maheshwari N
FAU - Shetty, P
AU  - Shetty P
FAU - Singh, R P
AU  - Singh RP
FAU - Ghate, S
AU  - Ghate S
FAU - Sacchidanand, S
AU  - Sacchidanand S
FAU - Tolat, S
AU  - Tolat S
FAU - Bhoira, Salman
AU  - Bhoira S
FAU - Marfatia, Y
AU  - Marfatia Y
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Dermatol
JT  - Indian journal of dermatology
JID - 0370750
PMC - PMC2807712
OTO - NOTNLM
OT  - Cefditoren pivoxil
OT  - uSSSI
OT  - uncomplicated skin and skin structure infection
COIS- Conflict of Interest: Nil.
EDAT- 2010/01/27 06:00
MHDA- 2010/01/27 06:01
PMCR- 2009/10/01
CRDT- 2010/01/27 06:00
PHST- 2010/01/27 06:00 [entrez]
PHST- 2010/01/27 06:00 [pubmed]
PHST- 2010/01/27 06:01 [medline]
PHST- 2009/10/01 00:00 [pmc-release]
AID - IJD-54-350 [pii]
AID - 10.4103/0019-5154.57612 [doi]
PST - ppublish
SO  - Indian J Dermatol. 2009;54(4):350-6. doi: 10.4103/0019-5154.57612.